Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19837538 | 0.87 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL19851391 | 0.85 | MBOAT4 (0.77) | MBOAT4 | |
| SCHEMBL19837445 | 0.85 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL19837534 | 0.85 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL19837567 | 0.83 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL19837346 | 0.82 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL19837578 | 0.82 | MBOAT4 (0.82) | MBOAT4 | |
| SCHEMBL19837316 | 0.82 | MBOAT4 (0.72) | MBOAT4 | |
| SCHEMBL19837573 | 0.82 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL19837568 | 0.81 | MBOAT4 (1.00) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49446-E1 | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-03-07 | — | — | US | disclosed |
| EP-3494120-B1 | OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-17 | — | — | EP | disclosed |
| EP-3494120-B1 | OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-17 | — | — | EP | disclosed |
| US-10308667-B2 | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-04 | — | — | US | disclosed |
| US-10308667-B2 | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20180251476-A1 | Oxadiazolopyridine Derivatives for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2018-09-06 | — | — | US | disclosed |
| US-9994591-B2 | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9994591-B2 | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9994591-B2 | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INERNATIONAL GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INERNATIONAL GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INERNATIONAL GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| WO-2018024653-A1 | OXADIAZOLOPYRIDINE DERIVATES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | MBOAT4, GIPR, ACAT1 | MBOAT4 1/4885 |
| US-20180251476-A1 | Oxadiazolopyridine Derivatives for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | MBOAT4, MOGAT2, ACAT1 | MBOAT4 1/4885 |
| US-10308667-B2 | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | MBOAT4, MOGAT2, ACAT1 | MBOAT4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.